David S. Siegel, MD, PhD

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses real-world outcomes with tandem transplantation in newly diagnosed multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on the escalating costs associated with cancer car

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.